Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ARGS > SEC Filings for ARGS > Form 8-K on 9-Mar-2017All Recent SEC Filings

Show all filings for ARGOS THERAPEUTICS INC

Form 8-K for ARGOS THERAPEUTICS INC


9-Mar-2017

Costs Associated with Exit or Disposal Activities, Change in Directors or


Item 2.05. Costs Associated with Exit or Disposal Activities

On March 8, 2017, the Board of Directors (the "Board") of Argos Therapeutics, Inc. (the "Company") approved a workforce action plan designed to streamline operations and reduce the Company's operating expenses. Under this plan, the Company plans to reduce its workforce by 46 employees (or 38%) from 122 employees to 76 employees. The principal objective of the reduction is to enable the Company to conserve its financial resources as the Company conducts its ongoing review of the preliminary ADAPT trial data set and discusses the data with the U.S. Food and Drug Administration ("FDA"), following which the Company will make a determination as to the next steps for the rocapuldencel-Tclinical program.

The Company expects that the workforce reduction will be substantially complete by the end of March 2017. The Company anticipates incurring approximately $1.3 million in total costs associated with the workforce reduction and that such costs will be incurred over the second and third quarters of 2017. The Company expects that the workforce reduction will decrease its annual operating costs by $5.7 million once the plan is fully implemented.

The Company is continuing to review the potential impact of the reduction in force and does not believe that there are any significant additional expenses at this time. If it subsequently determines that it will incur significant additional expenses, it will amend this Current Report on Form 8-K to disclose such information.



Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

In connection with the reduction in force described in Item 2.05 above, Joan C. Winterbottom, the Company's Vice President and Chief Human Resources Officer, will cease her employment with the Company effective March 17, 2017. In connection with Ms. Winterbottom's departure, the Compensation Committee of the Board determined to accelerate the vesting of Ms. Winterbottom's unvested restricted stock and stock options, such that all unvested restricted stock and stock options will become vested and exercisable in full on March 17, 2017. Ms. Winterbottom also will receive the severance payments and benefits provided for her in her Amended and Restated Employment Agreement dated as of June 10, 2016 with the Company.

Forward Looking Statements

Any statements in this Form 8-K about the Company's future expectations, plans and prospects, including statements about its strategy, future operations and financial obligations, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those discussed in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Any forward-looking statements contained in this Form 8-K speak only as of the date hereof and not of any future date, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

  Add ARGS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ARGS - All Recent SEC Filings
Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.